Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients: Results From the FEATHER Trial

Study Questions:

Does 5 mg of prasugrel in low-body-weight (LBW) patients achieve an equivalent antiplatelet effect as 10 mg in higher-body-weight (HMW) patients?